With a new Trade Mark Directive and Regulation, and the publication of its next five-year plan, 2016 is proving to be a key year for the EUIPO (formerly OHIM). James Nurton reports
Morten Garberg and Dirk Schüssler-Langeheine of Hoffmann Eitle outline how Europe’s IP regime may look after Brexit and explain what IP owners should be doing to prepare for it
As the UK seeks to forge a new relationship with the EU, Andreas Sætre Hanssen of Onsagers explains how another non-member, Norway, has managed its IP regime
Some IP owners doubt that software can be protected in Europe. David Robinson and Mike Williams of Marks & Clerk explain why they are wrong, and what owners of computer-implemented inventions can do to maximize their chances of securing a patent
Multinational companies and SMEs will need to think carefully about whether using the Unitary Patent and the UPC will save them money. Micaela Modiano and Alessandro Sanchini of Modiano outline the factors they need to take into account
The UK referendum result means that London is unlikely to play host to a UPC central division court. Cristina Biggi of Bugnion makes the case for Milan taking on the role
Trade mark proprietors continue to push the boundaries of protection for non-traditional trade marks. Simon Barker of Freeths explains how their marks can be protected in Europe and the UK
Germany and the UK both offer brand owners the means to protect unregistered IP rights. Angela Fox and Michael Nielen of Maucher Jenkins outline the similarities and differences between the rules in the two countries
The UK referendum result has created confusion over the future of the Unitary Patent and the Unified Patent Court. Marianne Schaffner of Dechert argues that EU member states must push ahead with the plan
Technological changes to the way that plants are developed and grown pose challenges to the way that plant breeders’ rights are protected. Ylva Skoglösa and Isabel Cantallops Fiol of Valea outline the problems and offer potential solutions
The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules
Busy week of MIP events!
#GlobalPatentForum tomorrow (Palo Alto) & Thur (Chicago)
#IPStrategyForum2017 Weds (London… https://t.co/nyW2gTKPTz
Emerging markets file more patents than the west https://t.co/FkQVfMMKyk via @FT (£)
Very sorry to hear this.
Wubbo received an outstanding achievement award from Managing IP in 2009… https://t.co/bz7via7FGz
Patent subject matter eligibility: A new Section 101
Calls for changing Section 101 of the Patent Act in the US are increasing. A proposed amendment from IPO shows one way to do it, reports Michael Loney
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International